Skip to main content
padlock icon - secure page this page is secure

Free Content Immune Checkpoint Inhibitor: An Emerging Treatment for Head and Neck Cancer. A Primer for the Radiologist

Download Article:
 Download
(HTML 145.3 kb)
 
or
 Download
(PDF 30,441.3 kb)
 
Immune checkpoint inhibitors have revolutionized treatment in many cancers, including head and neck squamous cell carcinoma. The number of drugs recently approved by the FDA and the European Medicine Agency is growing. Pembrolizumab and nivolumab, which are anti-programmed cell death protein 1 monoclonal antibodies, were first adopted in 2016 as the second-line treatment for recurrent or metastatic head and neck squamous cell carcinoma in patients with disease progression after platinum-based chemotherapy. Recently, pembrolizumab with or without platinum-based chemotherapy was approved as the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. Imaging studies play an essential role in assessing treatment response and monitoring efficacy and safety during and after treatments. Given the rapid increase in the use of immunotherapy in head and neck squamous cell carcinoma, neuroradiologists need to be familiar with the unique features indicative of treatment response in addition to a broad array of immune-related adverse events to avoid misinterpreting secondary drug-related adverse effects as tumor progression or metastasis. Moreover, emerging imaging techniques, including molecular imaging and radiomics, in an effort to assess or gauge the likelihood of treatment response to immune checkpoint inhibitors, is an ongoing area of active research.

Learning Objectives: To recognize the emerging role, basic mechanism, and unique treatment response patterns of immune checkpoint inhibitors for the treatment of head and neck cancer, and to describe imaging findings of immune-related adverse events of immune checkpoint inhibitors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: 89Zr = zirconium-89; CTLA-4 = cytotoxic T-lymphocyte‐associated antigen 4; HNSCC = head and neck squamous cell carcinoma; ICI = immune checkpoint inhibitor; NAE = neurologic adverse event; PD-L1 and PD-L2 = programmed cell death ligand 1 and 2; RECIST = Response Evaluation Criteria in Solid Tumors; anti‐PD-L1. Hyperprogression = programmed cell death protein 1; irAE = immune-related adverse event; irRC = immune-related response criteria

Document Type: Research Article

Publication date: October 1, 2020

More about this publication?
  • Neurographics is the peer-reviewed, bimonthly educational journal of the American Society of Neuroradiology. The journal comprises articles selected from material presented at the ASNR Annual Meeting. Neurographics also publishes other high-quality submissions that are primarily educational and have a high emphasis on a pictorial approach. Neurographics offers CME credit for reading review articles and completing quiz-based self-assessment activities.

    Visit the ASNR Education Connection to view all available CME courses.

  • Editorial Board
  • Information for Authors
  • Membership Information
  • Order a Print Copy
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more